Key statistics
On Friday, Zymeworks Inc (ZYME:NSQ) closed at 22.60, -20.67% below its 52-week high of 28.49, set on Nov 26, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 23.19 |
|---|---|
| High | 23.52 |
| Low | 22.49 |
| Bid | 22.25 |
| Offer | 22.83 |
| Previous close | 23.17 |
| Average volume | 554.07k |
|---|---|
| Shares outstanding | 74.84m |
| Free float | 71.45m |
| P/E (TTM) | -- |
| Market cap | 1.69bn USD |
| EPS (TTM) | -0.8448 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Announcements
- Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
- Zymeworks Outlines Strategic Priorities and Outlook for 2026
- Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
- Zymeworks Announces Participation in Upcoming Conferences
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
- Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
- Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
More ▼
